ABIRANOVA® in combination with prednisone or prednisolone is indicated for: -The treatment of newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT). -The treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. -The treatment of mCRPC in adult men whose disease has progressed during or after a docetaxel-based chemotherapy regimen.
CAPECINOVA® is indicated for adjuvant treatment after surgery in patients with stage III colon cancer (Dukes stage C) and as monotherapy in the first line of metastatic colorectal cancer. It is also indicated for the first line treatment of advanced gastric cancer with a platinum-containing regimen.
CAPECINOVA® in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. The previous therapy must have included an anthracycline. It is also indicated in monotherapy for patients with locally advanced or metastatic breast cancer after failure with taxanes and a chemotherapeutic regimen that includes an anthracycline or for those patients for whom no further therapy with anthracyclines is indicated.
CIPRONOVA® is indicated for non-tumoral female hirsutism and treatment for palliative prostate Cancer
DASANOVA® is indicated for the treatment of adult patients with:
DASANOVA® is indicated for the treatment of pediatric patients with:
Malignant pleural mesothelioma EKEL® in combination with Cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. Non-small cell lung cancer EKEL® is indicated in combination with Cisplatin for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer, except in patients with squamous cell histology. EKEL® is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer after prior chemotherapy, except in patients with squamous cell histology. EKEL® is indicated as monotherapy for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer, except in patients with squamous histology, whose disease has not progressed immediately after a platinum-based chemotherapy regimen.
GEFINOVA® is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with epidermal growth factor receptor protein kinase (TK-EGFR) activating mutations.
Gefitinb is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have previously received chemotherapy.
IMATINOVA® is indicated for the treatment of:
Myelodysplastic Syndrome (MDS): LENALINOVA® as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low or Intermediate-1 risk myelodysplastic syndromes linked to an isolated 5q deletion cytogenetic abnormality with or without additional cytogenetic abnormalities when other therapeutic options are insufficient or inadequate. Multiple Myeloma (MM): LENALINOVA® as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. LENALINOVA® in combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see “Posology and method of administration”) is indicated for the treatment of adult patients with previously untreated multiple myeloma (MM) who are not candidates for transplantation. . LENALINOVA® in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. Mantle Cell Lymphoma (MCL): LENALINOVA® as monotherapy is indicated for the treatment of adult patients with mantle cell lymphoma (MCL), who have relapsed or progressed after receiving two prior therapies, in one of the which Bortezomib has been used. Follicular Lymphoma: LENALINOVA® in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients who have received prior treatment for follicular lymphoma (Grade 1-3a).
First-line and subsequent therapy for the treatment of advanced ovarian carcinoma. As first-line therapy, Paclitaxel treatment is indicated in combination with cisplatin. Adjuvant treatment of breast cancer positive nodule, administered sequentially, with standard chemotherapy with combined doxorubicin. Treatment of breast cancer in cases where combined chemotherapy for metastasica disease or recurrence had failed within 6 months of adjuvant therapy. Pre-treatment should have included an anthracycline, unless it is clinically contraindicated. Paclitaxel, combined with cisplatin, is indicated as the first line of treatment for non-small cell lung cancer in patients unfit for potentially curative surgery and/or radiotherapy. Second line of treatment for AIDS-related Kaposi’s Sarcoma.
Treatment of patients with recent diagnosis of glioblastoma multiforme concomitantly with radiotherapy and later as adjuvant therapy, treatment of patients with malignant glioblastoma, such as glioblastoma multiforme or astrocytoma Anaplastic that present recurrence or progression after conventional therapy.
Bone metabolism regulator. Treatment of osteolytic and mixed bone metastases from solid tumors and osteolytic lesions of multiple myeloma, in conjunction with conventional antineoplastic therapy. Treatment of hypercalcaemia of malignant neoplasia (HM). therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
AZANOVA® is indicated for the treatment of adult patients who are not considered candidates for hematopoietic stem cell transplantation (HSCT) and who suffer for: -Intermediate 2 and high-risk myelodysplastic syndromes (MDS), according to the International Prognostic Scoring System (IPSS). -Chronic myelomonocytic leukemia (CMML) with 10 to 29% marrow blasts without myeloproliferative disorder. -Acute myeloid leukemia (AML) with 20 to 30% blasts and multilineage dysplasia, according to the WHO classification. -AML with >30% marrow blasts according to the WHO classification.
Legal disclaimer: the content of this web site has been created exclusively for healthcare professionals in order to keep them informed and guide them in the proper use of medications. All texts referring to prescription products correspond to the guidelines approved by the corresponding authority in each country where Celnova Pharma operates. This content has no promotional purposes and is not intended to replace healthcare professional recommendations. Celnova Pharma always recommends to consult a qualified healthcare professional for any inquiry regarding to a particular medical condition.